The #ChatGPT Clinic: An increasing number of people are turning to artificial intelligence #AI for #healthcare advice. According to an OpenAI report, on a global scale, more than 40 million people each day use ChatGPT to get answers to health care questions. #MedSky #HemeSky

MPN24, a #hematopoietic stem and progenitor cell-derived 24-gene weighted-sum expression score, was found to be prognostic of survival in #myelofibrosis, with a worse five-year OS observed in high-scoring patients versus low-scoring patients: https://ow.ly/KwNm50YpMLz#hematopoietic#myelofibrosis#HemeSky #MedSky

According to results from a recent phase II study, most patients with drug-resistant, true #extramedullary #myeloma responded to dual treatment with #talquetamab plus #teclistamab, with researchers observing a 61% PFS and 74% OS at 12 months: https://ow.ly/q6gI50YpblV#extramedullary#myeloma#talquetamab#teclistamab#MMsm #HemeSky #MedSky

In a recent phase II study, a time-limited, chemotherapy-free regimen guided by MRD monitoring achieved deep and durable responses in patients with previously untreated #MantleCellLymphoma #MCL, with CRs of 67% and 90% achieved in the studied cohorts: https://ow.ly/nf1V50YoEER#MantleCellLymphoma#MCL#HemeSky #MedSky

The March issue is out now! Issue highlights include a feature on #AI in medical education, a look at POEMS syndrome, dual-targeting therapy in #extramedullary #myeloma, and more. Check out the full issue lineup here: https://ow.ly/57Ym50YoBJm#AI#extramedullary#myeloma#HemeSky #MedSky

Prescription Price Plunge: New #Medicare negotiated drug prices for 2027 are set to make a big impact. The negotiated prices will save 36% or $8.5 billion in net covered #prescription costs. Included on the list of drugs are #leukemia and #breastcancer medications. #HemeSky #MedSky

The chemokine #CXCL9 has proven to be a reliable peripheral #blood biomarker of interferon-γ-driven #HLH, with elevated CXCL9 identifying adults with HLH who were at high risk for early mortality, irrespective of the underlying disease trigger: https://ow.ly/lj2r50Ym2fk#CXCL9#blood#HLH#HemeSky #MedSky

See what's to come in the next issue of ASH Clinical News! Below, Dr. Samuelson Bannow previews the March issue, with highlights including articles on #AI within medical education, #cytopenia concerns with #BCMA #bispecific #antibody use, and more: https://ow.ly/pK1i50Yl7R5#AI#cytopenia#BCMA#bispecific#antibody#HemeSky #MedSky

For patients with newly diagnosed #AML, an outpatient-based induction regimen of low-dose aza-ven plus #itraconazole performed better than with intensive #chemotherapy in a resource-limited setting, reducing early mortality and hospitalizations: https://ow.ly/hNoM50YkkWq#AML#itraconazole#chemotherapy#HemeSky #OncSky

Grants Gone Missing: Terminations of #grants from the #NIH have directly affected patients. In 2025, an estimated 74,311 patients were enrolled in active #clinical trials that had their funding terminated. Studies related to #cancer made up 2.7% of those that lost funding. #HemeSky #MedSky

A recent interim analysis suggests that a lower, pharmacokinetic-guided dosing of #emicizumab for #hemophiliaA, rather than a body weight dosing, may perform as effectively, with no statistical difference in ABRs observed between both dosing methods: https://ow.ly/pEnm50YhjUm#emicizumab#hemophiliaA#HemeSky #hemophilia

The combination of brentuximab vedotin and #nivolumab with #chemotherapy produced strong responses in treatment-naïve, non-bulky, early-stage classical #Hodgkin #lymphoma, with an ORR of 96% and estimated two-year PFS of 97% seen in study participants: https://ow.ly/lIQL50Yh9cy#nivolumab#chemotherapy#Hodgkin#lymphoma#HemeSky #OncSky

In #children with newly diagnosed #ImmuneThrombocytopenia #ITP requiring pharmacologic therapy, #eltrombopag demonstrated superior performance compared with standard therapy, resulting in a sustained #platelet response of 65% vs. 35%: https://ow.ly/GGa350Yf9aM#children#ImmuneThrombocytopenia#ITP#eltrombopag#platelet#PediatricHematology #HemeSky

#AI On Call: Artificial intelligence (AI) continues to make its way into #healthcare. Recent data found that 43% of medical residents use AI tools daily, but many noted concerns of overreliance or exceeding acceptable use with such tools. #MedSky #HemeSky

In older patients with de novo #AML without known adverse-risk cytogenetics, treatment with daunorubicin-cytarabine plus fractionated #gemtuzumab resulted in superior survival compared with CPX-351, with an OS of 52% vs. 35%, respectively, at three years: https://ow.ly/HGoV50Y9AUG#AML#gemtuzumab#HemeSky #OncSky

Elevate your practice with the latest breakthroughs in #hematology. Discover cutting-edge data in this collection of On Location video interviews from #ASH25, including new research in #MMsm, #CLL, and more: https://ow.ly/GqII50Y8i2V Wiley Clinical and Health #hematology#ASH25#MMsm#CLL#HemeSky #MedSky

The February issue is out now! Highlights include articles on the growing use of #AI in clinical #research, use of #DOACs in pediatric #thrombosis, public sector approaches to address unequal #CARTcell access, and more. Check out the full lineup here: https://ow.ly/LS7I50Y8gyW#AI#research#DOACs#thrombosis#CARTcell#HemeSky #MedSky

Low-dose DOACs substantially lowered the risk of #VTE in patients with newly diagnosed #MultipleMyeloma #MMsm, reducing VTE risk to 0.8% compared with an incidence of 5.6% and a risk of 9.8% in patients given prophylactic heparin and aspirin, respectively: https://ow.ly/oVNX50Y88ye#VTE#MultipleMyeloma#MMsm#HemeSky #OncSky

Just published! My take on the future of AI and hematology. Published in ASH clinical news yesterday. @ashclinicalnews.bsky.social ashpublications.org/ashclinicaln...

The High Price of Healing: The increasing cost of #healthcare is a worry for many #Americans. A survey revealed that six in 10 Americans are "extremely" or "very" worried about health care costs increasing in #2026, with many worried about accessing care and needed medications. #MedSKy #HemeSky

For patients with #hemophilia A and B with inhibitors, treatment with #marstacimab effectively reduced estimated annual bleeding rates, declining from 19.8 to 1.4, and significantly improved patients' quality of life by an estimated median of 25.9 points: https://ow.ly/SoLa50Y4z3V#hemophilia#marstacimab#HemeSky

With the rise of TKIs, the treatment landscape of #SystemicMastocytosis is changing, and the future looks promising. Join us on February 10 to learn as experts discuss the latest advances in TKI therapy, safety and side effects, and more. Register at https://ow.ly/mAUb50Y1kS3#SystemicMastocytosis#MedSky #mastocytosis

New research provides a #genomic framework with the ability to distinguish biologically malignant from indolent #myeloma precursor states in #MGUS and SMM, with key genomic alterations identified as predictors of faster progression in transformed cases: https://ow.ly/MWAm50Y1jFK#genomic#myeloma#MGUS#HemeSky #MMsm

Care on Hold: Prior authorization may directly affect patients with #cancer, according to an analysis which found that 74% of patients had to seek prior authorization for their treatment, and 50% were directly involved in the authorization process. #MedSky #OncSky

The January issue is out now! Issue highlights include meeting coverage and reports from #ASH25, a feature on #patient support programs, updates on international guidelines for #pediatric #AcuteMyeloidLeukemia #AML, and more. See the full lineup here: https://ow.ly/tgpq50Y0C89

RD118, a new anti-GPRC5D #CARTtherapy, may be an effective therapeutic option in heavily pretreated cases of #MultipleMyeloma #MMsm, including those relapsing after BCMA therapy, according to phase I research resulting in a durable ORR of 94.4%: https://ow.ly/FQGQ50XXspe#CARTtherapy#MultipleMyeloma#MMsm#HemeSky #MyelomaSky

Among older and frail patients with #MultipleMyeloma #MMsm, a dexamethasone-sparing regimen with #daratumumab and #lenalidomide reduced the risk of progression or death compared with lenalidomide and #dexamethasone alone, at a PFS of 53.4 vs. 22.5 months: https://ow.ly/YXzG50XT7Aw#MultipleMyeloma#MMsm#daratumumab#lenalidomide#dexamethasone#HemeSky #OncSky

According to recent research, peripheral #blood testing may offer a reliable, minimally invasive alternative to bone marrow evaluation for somatic mutation surveillance in #pediatric patients with #BoneMarrowFailure and #leukemia predisposition syndromes: https://ow.ly/TTeZ50XUak8#blood#pediatric#BoneMarrowFailure#leukemia#HemeSky #MedSky

See what's to come in this month's issue! Editor-in-Chief Bethany Samuelson Bannow, MD, MCR (she/her) shares what readers can expect, including coverage from #ASH25, a feature on #patient assistance programs, a challenging case of refractory #Hodgkin #lymphoma, and more: https://ow.ly/Bnww50XT7Uw

New data point to an association between medical imaging #radiation and an increased risk of #hematologic #cancer in children and adolescents, with researchers estimating 10.1% of hematologic cancers may have been attributable to such radiation exposure: https://ow.ly/KEzp50XSwSs#radiation#hematologic#cancer#HemeSky #OncSky

Recent research indicates that #isatuximab monotherapy could be another safe and effective treatment option for patients with R/R #amyloidosis, with the therapy resulting in an ORR of 77%, including 57% with a VGPR or better: https://ow.ly/wbFU50XNrsR#isatuximab#amyloidosis#HemeSky

Chemo-free combination therapy with ATRA-ATO produced a significantly higher two-year EFS than SOC ATRA plus #chemotherapy among patients with newly diagnosed, high-risk acute promyelocytic #leukemia at 88% vs. 71%: https://ow.ly/kjxH50XNnbU#chemotherapy#leukemia#HemeSky #OncSky

KP104, a #monoclonal #antibody used to treat #PNH, continues to display strong clinical efficacy two years after treatment, with 100% of participants maintaining an Hb increase of at least 2 g/dL from baseline and 89% achieving Hb normalization by then: https://ow.ly/veiT50XNmTt#monoclonal#antibody#PNH#HemeSky

Compared with #obinutuzumab monotherapy, the next-gen BTK inhibitor #zanubrutinib in combination with #obinutuzumab led to improved survival in patients with #FollicularLymphoma, resulting in ORRs of 70.3% vs. 44.4% and PFS of 22.1 vs. 10.3 months: https://ow.ly/qzV250XMMvj#obinutuzumab#zanubrutinib#obinutuzumab#FollicularLymphoma#HemeSky #MedSky

Antibody-based combination therapy with #teclistamab and #daratumumab was shown to be highly effective in elderly patients with newly diagnosed #MultipleMyeloma #MMsm, producing a VGPR or better in 79% of patients and MRD negativity in 100% at six months: https://ow.ly/KQKn50XMHAW#teclistamab#daratumumab#MultipleMyeloma#MMsm#HemeSky #MedSky

A 600 mg daily dose of the menin inhibitor #ziftomenib, combined with venetoclax and azacitidine, demonstrated robust clinical activity in patients with newly diagnosed, NPM1-mutated #AcuteMyeloidLeukemia #AML at an 84% CRc and an MRD-negative rate of 54%: https://ow.ly/E5Nb50XMwL0#ziftomenib#AcuteMyeloidLeukemia#AML#HemeSky #OncSky

For patients with #PolycythemiaVera, #rusfertide provided durable, sustained hematocrit control that stayed below 43% and reduced #phlebotomy requirements up to 52 weeks, with 61.9% of patients remaining ineligible for phlebotomy between 0-52 weeks: https://ow.ly/KYiZ50XKVRT#PolycythemiaVera#rusfertide#phlebotomy#HemeSky #MedSky

For patients with myeloid/lymphoid #neoplasms with FGFR1 rearrangements, #pemigatinib led to high rates of complete clinical and cytogenetic responses in chronic-phase disease, at 96% and 88%, respectively, with encouraging activity in blast-phase disease: https://ow.ly/UKCT50XKhvX#neoplasms#pemigatinib#HemeSky #OncSky

According to a recent analysis of the iStopMM study, individuals with smoldering multiple myeloma #MMsm (SMM) had a 36% higher risk of infections compared with individuals with MGUS or those without either SMM or MGUS: https://ow.ly/RWcE50XH9Nz#MMsm#HemeSky #myeloma

#ASH25 In patients with #myelofibrosis, the mutant CALR-specific monoclonal antibody INCA33989 was well tolerated as monotherapy or in combination with #ruxolitinib, with 37% and 30% of patients having SVR25 and SVR35, respectively, at 24 weeks: https://ow.ly/4FX950XF6zZ#ASH25#myelofibrosis#ruxolitinib#HemeSky #MedSky

#ASH25 The BCL2 inhibitor #sonrotoclax produced good responses in patients with treatment-naïve CLL/SLL when combined with #obinutuzumab, with ORRs of 89% across all patients and 93% at a 320 mg dose: https://ow.ly/M8uB50XF6zT#ASH25#sonrotoclax#obinutuzumab#HemeSky #MedSky

#ASH25 In the first head-to-head study of the two drugs, #pirtobrutinib was found to produce ORRs that were noninferior to those seen with #ibrutinib in both the intent-to-treat and R/R population of patients with #CLL: https://ow.ly/WIEg50XExWA#ASH25#pirtobrutinib#ibrutinib#CLL#HemeSky #OncSky

#ASH25 Among patients with #ChronicLymphocyticLeukemia, fixed-duration targeted treatment using venetoclax-based combinations was found to achieve efficacy comparable to #BTKi therapy, with 3-year PFS ranging from 79% to 81% across all treatment arms: https://ow.ly/LOkJ50XExRg#ASH25#ChronicLymphocyticLeukemia#BTKi#HemeSky #OncSky

#ASH25 Based on findings from the largest prospective analysis of #renal impairment in patients with #PolycythemiaVera (PV), a history of #thromboembolism, high-risk PV, and elevated LDH were found to be associated with rapid decline in #kidney function: https://ow.ly/AmqA50XExMH#ASH25#renal#PolycythemiaVera#thromboembolism#kidney#HemeSky #MedSky

A frailty-score-adapted treatment regimen of an oral PI/IMiD combination improved early treatment cessation, PFS, and OS in unfit patients with #MultipleMyeloma #MMsm but not in frail patients, according to research to presented at #ASH25: https://ow.ly/rtun50XCYcp#MultipleMyeloma#MMsm#ASH25#HemeSky #MyelomaSky

#ASH25 Anito-cel, a new anti-BMCA #CARTcell therapy with a unique D-domain binder that may lead to more therapeutic efficacy, was found to produce strong rates of response in patients with R/R #MultipleMyeloma #MMsm, with an ORR of 97% and CR/sCR of 68%: https://ow.ly/P9Gj50XCNnl#ASH25#CARTcell#MultipleMyeloma#MMsm#HemeSky #OncSky

Results from the phase II Shorespan-004 trial, to be presented at #ASH25, indicate that oral #bomedemstat effectively reduced hematocrit to less than 45% by week 36 in 45% of patients with previously treated #PolycythemiaVera: https://ow.ly/2bmS50XCMyM#ASH25#bomedemstat#PolycythemiaVera#HemeSky #MedSky

Imaging's Hidden Cost: There may be a link between #medical #imaging and childhood #BloodCancers. A retrospective cohort study found that 10.1% of #hematologic cancers in children may be caused by #radiation exposure from medical imaging. #HemeSky #OncSky

The December issue is available now! Check out the link below to read articles on #isatuximab for R/R AL #amyloidosis, ATRA-ATO combination therapy for APL, #pemigatinib for myeloid & lymphoid #neoplasms with FGFR1 rearrangements, and more: https://ow.ly/fzzm50XARLQ

A longer time from T-cell collection to infusion of #CARTcell therapy was associated with worse outcomes, particularly with regard to PFS and OS, in patients with R/R #DLBCL, according to findings from a small retrospective trial conducted in Japan: https://ow.ly/SwTh50XAlhw